Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis - Summary - MDSpire

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

  • By

  • Geert D’Haens

  • Silvio Danese

  • Remo Panaccione

  • David T Rubin

  • Laurent Peyrin-Biroulet

  • Katsuyoshi Matsuoka

  • Edward V Loftus

  • Taku Kobayashi

  • Walid Elsharkawi

  • Rosa Miceli

  • Samia Ahmed

  • Yi Luo

  • Andrew Napoli

  • John Vaile

  • Quentin Dornic

  • Aditya Patel

  • Stefan Schreiber

  • May 13, 2025

  • 0 min

Share

Objective:

To evaluate the efficacy and safety of deucravacitinib in patients with moderately to severely active Crohn's disease and ulcerative colitis, focusing on primary endpoints.

Key Findings:
  • Primary endpoints were not met for all three studies, leading to early termination for LATTICE-CD and IM011-127, raising concerns about the drug's efficacy.
  • High efficacy rates were observed in placebo groups throughout the studies, indicating potential placebo effects.
Interpretation:

Deucravacitinib did not demonstrate significant clinical benefit compared to placebo in treating moderately to severely active Crohn's disease or ulcerative colitis, highlighting the need for further investigation.

Limitations:
  • The studies were terminated early due to lack of efficacy, which may introduce bias.
  • The sample sizes were relatively small, particularly in IM011-127, limiting the generalizability of the findings.
Conclusion:

Deucravacitinib was found to be safe and well tolerated, but did not show significant efficacy in the treatment of inflammatory bowel disease, suggesting a need for alternative therapeutic strategies.

Original Source(s)

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

  • by Geert D’Haens, Silvio Danese, Remo Panaccione, David T Rubin, Laurent Peyrin-Biroulet, Katsuyoshi Matsuoka, Edward V Loftus, Taku Kobayashi, Walid Elsharkawi, Rosa Miceli, Samia Ahmed, Yi Luo, Andrew Napoli, John Vaile, Quentin Dornic, Aditya Patel, Stefan Schreiber

  • May 13, 2025

Related Content

Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists

Assessment of the quality and dependability of Crohn's disease-related information on Douyin and Xiaohongshu: Insights from user feedback in a cross-sectional analysis

Progression of Coronary Calcium Detected on Routine Chest CT Enhances Cardiovascular Risk Assessment in Individuals with Inflammatory Bowel Disease: Findings from a Multicenter Study